

Hannah Y Wen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/858524/publications.pdf>

Version: 2024-02-01

67
papers

2,730
citations

257450

24
h-index

206112

48
g-index

68
all docs

68
docs citations

68
times ranked

4862
citing authors

#	ARTICLE	IF	CITATIONS
1	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
2	Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. <i>JAMA Oncology</i> , 2022, 8, 607.	7.1	147
3	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	9.4	139
4	A phase 2 clinical trial—assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. <i>Cancer</i> , 2020, 126, 850-860.	4.1	116
5	Whole-genome single-cell copy number profiling from formalin-fixed paraffin-embedded samples. <i>Nature Medicine</i> , 2017, 23, 376-385.	30.7	111
6	Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas. <i>Nature Communications</i> , 2018, 9, 1816.	12.8	105
7	Genetic alterations of triple negative breast cancer by targeted next-generation sequencing and correlation with tumor morphology. <i>Modern Pathology</i> , 2016, 29, 476-488.	5.5	95
8	The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1030-1034.	6.3	90
9	The Genomic Landscape of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 737-741.	6.3	68
10	Lobular Carcinoma In Situ. <i>Surgical Pathology Clinics</i> , 2018, 11, 123-145.	1.7	58
11	Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 3030-3035.	7.1	52
12	Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. <i>Nature Medicine</i> , 2022, 28, 946-957.	30.7	50
13	Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family. <i>Modern Pathology</i> , 2017, 30, 69-84.	5.5	48
14	Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential. <i>Histopathology</i> , 2019, 75, 213-224.	2.9	46
15	Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 2556-2562.	1.5	45
16	Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 61-66.	2.5	42
17	Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma In Situ to Invasive Ductal Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3682-3693.	7.0	42
18	Homologous recombination DNA repair defects in PALB2-associated breast cancers. <i>Npj Breast Cancer</i> , 2019, 5, 23.	5.2	39

#	ARTICLE	IF	CITATIONS
19	Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. <i>Npj Breast Cancer</i> , 2021, 7, 96.	5.2	38
20	Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. <i>Histopathology</i> , 2015, 67, 529-537.	2.9	37
21	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1056-1064.	5.5	35
22	21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 69-76.	2.5	31
23	Somatic mutations in leukocytes infiltrating primary breast cancers. <i>Npj Breast Cancer</i> , 2015, 1, 15005.	5.2	30
24	The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 65-76.	2.5	28
25	The genomic landscape of metastatic histologic special types of invasive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 53.	5.2	27
26	Breast Cancers of Special Histologic Subtypes Are Biologically Diverse. <i>Annals of Surgical Oncology</i> , 2018, 25, 3158-3164.	1.5	26
27	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020, 33, 354-366.	5.5	25
28	Pleomorphic adenomas and mucoepidermoid carcinomas of the breast are underpinned by fusion genes. <i>Npj Breast Cancer</i> , 2020, 6, 20.	5.2	25
29	The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features. <i>Modern Pathology</i> , 2022, 35, 193-201.	5.5	25
30	Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma. <i>Histopathology</i> , 2019, 75, 139-145.	2.9	22
31	Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast: a 12-year prospective clinical study. <i>Modern Pathology</i> , 2018, 31, 956-964.	5.5	21
32	Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas. <i>Npj Breast Cancer</i> , 2019, 5, 6.	5.2	21
33	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	4.6	21
34	The Landscape of Somatic Genetic Alterations in Breast Cancers from CHEK2 Germline Mutation Carriers. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz027.	2.9	20
35	Immunohistochemical assessment of HRASQ61R mutations in breast adenomyoepitheliomas. <i>Histopathology</i> , 2020, 76, 865-874.	2.9	19
36	Chromatin-informed inference of transcriptional programs in gynecologic and basal breast cancers. <i>Nature Communications</i> , 2019, 10, 4369.	12.8	18

#	ARTICLE	IF	CITATIONS
37	Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer. <i>Scientific Reports</i> , 2021, 11, 12781.	3.3	17
38	Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up. <i>Cancer</i> , 2017, 123, 131-137.	4.1	16
39	Whole-exome sequencing and RNA sequencing analyses of acinic cell carcinomas of the breast. <i>Histopathology</i> , 2019, 75, 931-937.	2.9	16
40	TERT promoter hotspot mutations and gene amplification in metaplastic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 43.	5.2	16
41	The 21-Gene Recurrence Score in Male Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 1530-1535.	1.5	14
42	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IMTA study. <i>Modern Pathology</i> , 2021, 34, 2130-2140.	5.5	14
43	Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome. <i>Clinical Cancer Research</i> , 2022, 28, 404-413.	7.0	13
44	Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 1132-1137.	2.5	11
45	Breast conservation among older patients with early-stage breast cancer: Locoregional recurrence following adjuvant radiation or hormonal therapy. <i>Cancer</i> , 2021, 127, 1749-1757.	4.1	11
46	Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing. <i>Modern Pathology</i> , 2019, 32, 81-87.	5.5	10
47	Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number <4.0 and <6.0. <i>Archives of Pathology and Laboratory Medicine</i> . 2020, 144, 597-601.	2.5	10
48	Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up. <i>BMC Cancer</i> , 2018, 18, 42.	2.6	9
49	Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system. <i>Breast Journal</i> , 2019, 25, 829-837.	1.0	9
50	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. <i>Annals of Surgical Oncology</i> , 2019, 26, 329-335.	1.5	9
51	Extranodal Tumor Deposits in the Axillary Fat Indicate the Need for Axillary Dissection Among T1-T2cN0 Patients with Positive Sentinel Nodes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3585-3592.	1.5	9
52	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
53	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. <i>Cancers</i> , 2021, 13, 6273.	3.7	9
54	Atypical ductal hyperplasia bordering on DCIS on core biopsy is associated with higher risk of upgrade than conventional atypical ductal hyperplasia. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 873-880.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?. Breast Journal, 2020, 26, 1199-1207.	1.0	8
56	Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation. Histopathology, 2020, 77, 321-326.	2.9	7
57	Next-generation assessment of human epidermal growth factor receptor 2 gene (<i>ERBB2</i>) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology, 2021, 78, 498-507.	2.9	7
58	HER2 Immunohistochemistry in Invasive Micropapillary Breast Carcinoma: Complete Assessment of an Incomplete Pattern. Archives of Pathology and Laboratory Medicine, 2021, 145, 979-987.	2.5	7
59	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. Breast Cancer Research and Treatment, 2022, 191, 423-430.	2.5	6
60	Neuroendocrine tumours of the breast: a genomic comparison with mucinous breast cancers and neuroendocrine tumours of other anatomic sites. Journal of Clinical Pathology, 2020, , jclinpath-2020-207052.	2.0	5
61	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. Annals of Surgical Oncology, 2021, 28, 4256-4262.	1.5	5
62	Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. Journal of Pathology: Clinical Research, 2021, 7, 113-120.	3.0	4
63	Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy. Modern Pathology, 2021, 34, 1310-1319.	5.5	3
64	Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes. Modern Pathology, 2021, 34, 1850-1859.	5.5	3
65	Stromal <i>MED12</i> exon 2 mutations in complex fibroadenomas of the breast. Journal of Clinical Pathology, 2022, 75, 133-136.	2.0	2
66	Quality Issues in Diagnostic Immunohistochemistry in Breast Pathology. Pathobiology, 2022, , 1-10.	3.8	2
67	Reply to "Multicentric Ipsilateral Invasive Breast Carcinomas Might Have Higher 21-Gene Recurrence Score Compared with Multifocal Ipsilateral Invasive Breast Carcinomas". Annals of Surgical Oncology, 2019, 26, 310-311.	1.5	1